TABLE 2.

Treatment effectiveness, healthcare utilization and health state utility value (HSUV) inputs

	Input value	Included in OWSAs and PSA	Standard deviation in PSA	Distribution	Source
Treatment effectiveness	1.81	Yes	0.123 (log scale)	logNormal	30
Percentage of critical patients among severe patients	17.5%	No	NA	NA	35
Costs of RT‐PCR/test	Cn¥160	Yes	10% of mean	Gamma	33
One‐time visit costs	Cn¥500	No	NA	NA	Assumption
Daily bed costs	Cn¥11	No	NA	NA	34
SoC medication costs of moderate patients/d	Cn¥898	Yes	10% of mean	Gamma	34
SoC medication costs of severe patients/d	Cn¥2375	Yes	10% of mean	Gamma	34
SoC medical costs of moderate patients/d	Cn¥582	Yes	10% of mean	Gamma	34
SoC medical costs of severe patients/d	Cn¥1538	Yes	10% of mean	Gamma	34
Acquisition costs of 5‐day remdesivir regimen	CN¥16 600	Yes	10% of mean	Gamma	6
Utility weight of the W class	0.626	No	NA	NA	Estimated
Utility weight of the mild patients	0.995	No	NA	NA	36
Utility weight of the moderate patients	0.614	Yes	10% of mean	Beta	36
Utility weight of the severe patients	0.588	Yes	10% of mean	Beta	36
QALY loss/Covid‐19 death	11.27	No	NA	NA	22 , 37 , 38

Abbreviation: OWSA, 1‐way sensitivity analysis; PSA, probabilistic sensitivity analysis; NA, not applicable; RT‐PCR, reverse transcription–polymerase chain reaction; SoC, standard of care; QALY, quality‐adjusted life year.